Patients

Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe
Clinical News

Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe

The European Medicines Agency (EMA)’s safety committee (PRAC) has concluded that there is no evidence Zynteglo causes a blood cancer known as acute myeloid leukaemia (AML). Zynteglo, a gene therapy…
Clinical Trials Update: The June 2021 Edition
Clinical News

Clinical Trials Update: The June 2021 Edition

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
The June Update: TIF’s Guide On COVID-19 Vaccinations & Therapeutic Drugs
News

The June Update: TIF’s Guide On COVID-19 Vaccinations & Therapeutic Drugs

As vaccination rates are slowing in the US and Europe, the spread of the Delta coronavirus variants causes growing concerns worldwide with health experts predicting the highly infectious variant to…
TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education
TIF News

TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Clinical News

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. announced that it has submitted a New Drug Application (NDA) for Mitapivat to the U.S. Food and Drug Administration (FDA) for the treatment of adults with pyruvate…
New Paper From Blood and Beyond Outlines How To Learn From The Impact Of The COVID-19 Crisis On Blood Use
News

New Paper From Blood and Beyond Outlines How To Learn From The Impact Of The COVID-19 Crisis On Blood Use

The multi-stakeholder Blood and Beyond initiative recently published a policy briefing shedding light on how the COVID-19 pandemic affects blood use, blood transfusion services, and patients in whom transfusions are…
MONTHLY UPDATE: COVID-19 Developing Vaccinations & Therapeutic Drugs
Publications

MONTHLY UPDATE: COVID-19 Developing Vaccinations & Therapeutic Drugs

All the latest updates of TIF’s Vaccinations & Therapeutic Drugs Guide for COVID-19 gathered in one single document.
Ali Sattarpour: ”Thalassaemia did not stop me from living a normal life”
News

Ali Sattarpour: ”Thalassaemia did not stop me from living a normal life”

In occasion of the International Thalassaemia Day 2021, Ali Sattarpour, 45, France, Fédération SOS GLOBI Vice President and TIF’s Thalassaemia Patient Advocacy Group (T-PAG) Member, recounts a life of struggles,…
TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia
News

TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia

The Thalassaemia International Federation (TIF) expresses its disappointment about the outcome of the reimbursement negotiation process concerning gene therapy (Zynteglo™) for transfusion-dependent thalassaemia patients, announced last week. The Federation’s distress…
Back to top button